Literature DB >> 9166661

Impact of natural IRS-1 mutations on insulin signals: mutations of IRS-1 in the PTB domain and near SH2 protein binding sites result in impaired function at different steps of IRS-1 signaling.

R Yoshimura1, E Araki, S Ura, M Todaka, K Tsuruzoe, N Furukawa, H Motoshima, K Yoshizato, K Kaneko, K Matsuda, H Kishikawa, M Shichiri.   

Abstract

Insulin receptor substrate-1 (IRS-1) is one of the major substrates of insulin receptor tyrosine kinase and mediates various insulin signals downstream. In this study, we have examined the impact of three natural IRS-1 mutations identified in NIDDM patients (G971R, P170R, and M209T) on insulin signaling. G971R is located near src homology 2 protein binding sites, and P170R and M209T are located in the phosphotyrosine binding domain of IRS-1. 32D-IR cells, stably overexpressing human insulin receptor, were transfected with wild-type human IRS-1 cDNA (WT) or three mutant IRS-1 cDNAs and analyzed. All the cell lines expressing mutant IRS-1 showed a significant reduction in [3H]thymidine incorporation compared with WT. Upon insulin stimulation, cells expressing G971R showed a 39% decrease (P < 0.005) in phosphatidylinositol 3-kinase (PI 3-kinase) activity, a 43% decrease (P < 0.01) in binding of the 85-kDa regulatory subunit of PI 3-kinase, and a 22% decrease (P < 0.05) in mitogen-activated protein kinase activity compared with those expressing WT. Cells expressing P170R and M209T showed slight but significant decreases in PI 3-kinase activity (17 and 14%, respectively; both P < 0.05) and in binding of p85 (22 and 16%, respectively; both P < 0.05) and a greater decrease in mitogen-activated protein kinase activity (41 and 43%, respectively; both P < 0.005) compared with WT. After insulin stimulation, cells expressing P170R and M209T showed significant decreases in IRS-1 phosphorylation (37 and 42%, respectively; both P < 0.05) and in IRS-1 binding to the insulin receptor (48 and 53%, respectively; P < 0.01) compared with WT. G971R showed no changes in IRS-1 phosphorylation and in IRS-1 binding to the insulin receptor compared with WT. These data suggest that the impaired mitogenic response of P170R and M209T was mainly due to reduced binding to the insulin receptor, whereas the impaired response of G971R was mainly due to reduced association with PI 3-kinase p85.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166661     DOI: 10.2337/diab.46.6.929

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  14 in total

Review 1.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

2.  Numb modifies neuronal vulnerability to amyloid beta-peptide in an isoform-specific manner by a mechanism involving altered calcium homeostasis: implications for neuronal death in Alzheimer's disease.

Authors:  Sic L Chan; Ward A Pedersen; Hiayan Zhu; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 3.  Genetics of insulin resistance.

Authors:  Maria M Mercado; John C McLenithan; Kristi D Silver; Alan R Shuldiner
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

4.  Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies.

Authors:  A Jellema; M P A Zeegers; E J M Feskens; P C Dagnelie; R P Mensink
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

5.  Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus.

Authors:  Hasniza Zaman Huri; Mohd Makmor-Bakry; Rosnani Hashim; Norlaila Mustafa; Wan Zurinah Wan Ngah
Journal:  Int J Clin Pharm       Date:  2012-08-07

6.  Association between IRS-1 Gly972Arg polymorphism and colorectal cancer risk.

Authors:  Peng Li; Lingjun Wang; Lihua Liu; Hong Jiang; Chong Ma; Tao Hao
Journal:  Tumour Biol       Date:  2014-04-03

7.  A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.

Authors:  Yuan C Ding; Lesley McGuffog; Sue Healey; Eitan Friedman; Yael Laitman; Shani- Paluch-Shimon; Bella Kaufman; Annelie Liljegren; Annika Lindblom; Håkan Olsson; Ulf Kristoffersson; Marie Stenmark-Askmalm; Beatrice Melin; Susan M Domchek; Katherine L Nathanson; Timothy R Rebbeck; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska; Katarzyna Durda; Jacek Gronwald; Tomasz Huzarski; Cezary Cybulski; Tomasz Byrski; Ana Osorio; Teresa Ramóny Cajal; Alexandra V Stavropoulou; Javier Benítez; Ute Hamann; Matti Rookus; Cora M Aalfs; Judith L de Lange; Hanne E J Meijers-Heijboer; Jan C Oosterwijk; Christi J van Asperen; Encarna B Gómez García; Nicoline Hoogerbrugge; Agnes Jager; Rob B van der Luijt; Douglas F Easton; Susan Peock; Debra Frost; Steve D Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Fiona Lalloo; Louise Izatt; Ros Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Andrew K Godwin; Harsh Pathak; Dominique Stoppa-Lyonnet; Olga M Sinilnikova; Sylvie Mazoyer; Laure Barjhoux; Mélanie Léoné; Marion Gauthier-Villars; Virginie Caux-Moncoutier; Antoine de Pauw; Agnès Hardouin; Pascaline Berthet; Hélène Dreyfus; Sandra Fert Ferrer; Marie-Agnès Collonge-Rame; Johanna Sokolowska; Saundra Buys; Mary Daly; Alex Miron; Mary Beth Terry; Wendy Chung; Esther M John; Melissa Southey; David Goldgar; Christian F Singer; Muy-Kheng Maria Tea; Daphne Gschwantler-Kaulich; Anneliese Fink-Retter; Thomas V O Hansen; Bent Ejlertsen; Oskar T Johannsson; Kenneth Offit; Kara Sarrel; Mia M Gaudet; Joseph Vijai; Mark Robson; Marion R Piedmonte; Lesley Andrews; David Cohn; Leslie R DeMars; Paul DiSilvestro; Gustavo Rodriguez; Amanda Ewart Toland; Marco Montagna; Simona Agata; Evgeny Imyanitov; Claudine Isaacs; Ramunas Janavicius; Conxi Lazaro; Ignacio Blanco; Susan J Ramus; Lara Sucheston; Beth Y Karlan; Jenny Gross; Patricia A Ganz; Mary S Beattie; Rita K Schmutzler; Barbara Wappenschmidt; Alfons Meindl; Norbert Arnold; Dieter Niederacher; Sabine Preisler-Adams; Dorotehea Gadzicki; Raymonda Varon-Mateeva; Helmut Deissler; Andrea Gehrig; Christian Sutter; Karin Kast; Heli Nevanlinna; Kristiina Aittomäki; Jacques Simard; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Gail E Tomlinson; Jeffrey Weitzel; Judy E Garber; Olufunmilayo I Olopade; Wendy S Rubinstein; Nadine Tung; Joanne L Blum; Steven A Narod; Sean Brummel; Daniel L Gillen; Noralane Lindor; Zachary Fredericksen; Vernon S Pankratz; Fergus J Couch; Paolo Radice; Paolo Peterlongo; Mark H Greene; Jennifer T Loud; Phuong L Mai; Irene L Andrulis; Gord Glendon; Hilmi Ozcelik; Anne-Marie Gerdes; Mads Thomassen; Uffe Birk Jensen; Anne-Bine Skytte; Maria A Caligo; Andrew Lee; Georgia Chenevix-Trench; Antonis C Antoniou; Susan L Neuhausen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-22       Impact factor: 4.254

8.  ASSOCIATION OF IRS1 GLY971ARG GENE POLYMORPHISM WITH INSULIN RESISTANCE IN IRANIAN NEWLY DIAGNOSED DIABETIC ADULTS.

Authors:  H Shakeri; A Khoshi; M Kaffash Bajestani; A Farahi; M S Javadzadeh; Z Hosseini; R Mohammadi
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

9.  The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells.

Authors:  O Porzio; M Federici; M L Hribal; D Lauro; D Accili; R Lauro; P Borboni; G Sesti
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

10.  The Gly(972)Arg variant of human IRS1 gene is associated with variation in glomerular filtration rate likely through impaired insulin receptor signaling.

Authors:  Farook Thameem; Sobha Puppala; Jennifer Schneider; Basant Bhandari; Rector Arya; Nedal H Arar; Tetyana L Vasylyeva; Vidya S Farook; Sharon Fowler; Laura Almasy; John Blangero; Ravindranath Duggirala; Hanna E Abboud
Journal:  Diabetes       Date:  2012-05-22       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.